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Exome sequencing studies have generally been underpowered to identify deleterious 88 
alleles with a large effect on complex traits, as such alleles are mostly rare. Because the 89 
population of northern and eastern Finland has expanded dramatically and in isolation 90 
following a series of bottlenecks, it harbors numerous deleterious alleles at relatively high 91 
frequency. Capitalizing on this circumstance, we exome sequenced nearly 20,000 92 
individuals from these regions. Exome-wide association studies for 64 quantitative traits 93 
clinically relevant to cardiovascular and metabolic disease identified 26 newly associated 94 
deleterious alleles. Nineteen of these alleles are either unique to or >20 times more frequent 95 
in Finns than in other Europeans and show geographical clustering comparable to 96 
Mendelian disease mutations characteristic of the Finnish population. We estimate that 97 
sequencing studies in populations without this unique history would require hundreds of 98 
thousands to millions of participants to achieve comparable association power.  99 
 100 
INTRODUCTION 101 
Most alleles with a demonstrated deleterious effect on phenotypes directly alter protein 102 
structure or function1,2. Exome sequencing studies aim to discover such alleles and 103 
demonstrate their association to common diseases and disease-related quantitative traits. 104 
However, exome sequencing studies to date generally have identified few newly associated 105 
rare variants or genes3,4. The sample size required for such discoveries remains uncertain 106 
and theoretical analyses indicate that studies to date have been underpowered, since most 107 
deleterious variants are expected to be rare due to purifying selection5. These previous 108 
analyses also suggest that power to detect associations to deleterious alleles is greatest in 109 
 
 4 
populations that have expanded in isolation after recent bottlenecks, as alleles passing 110 
through the bottlenecks may rise to much higher frequencies than in other populations6-8.  111 
 112 
Finland exemplifies such a history. Bottlenecks occurred at the founding of early-113 
settlement regions (southern and western Finland) 2,000-4,000 years ago and again with 114 
internal migration to late-settlement regions (northern and eastern Finland) in the 15th and 115 
16th centuries9. Finland’s subsequent population growth (to ~5.5 million) generated sizable 116 
geographic sub-isolates in late-settlement regions.  117 
 118 
This unique population history has resulted in “the Finnish Disease Heritage”10, 36 119 
Mendelian diseases that are much more common in Finns than in other Europeans. These 120 
disorders concentrate in late-settlement regions of Finland10, and the genes responsible for 121 
them exhibit extreme enrichment of deleterious variants11-13. We created the FinMetSeq 122 
study to capitalize on the population history of late-settlement Finland to discover rare-123 
variant associations with cardiovascular and metabolic disease-relevant quantitative traits 124 
through exome sequencing of two extensively phenotyped population cohorts, FINRISK 125 
and METSIM (Methods).  126 
 127 
We successfully sequenced 19,292 FinMetSeq participants and tested the identified 128 
variants for association with 64 clinically relevant quantitative traits, discovering 43 novel 129 
associations with deleterious variants14,15: 19 associations (11 traits) in FinMetSeq alone 130 
and 24 associations (20 traits) in a combined analysis of FinMetSeq with 24,776 Finns 131 
from three cohorts with imputed genome-wide genotypes. Nineteen of the 26 variants 132 
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underlying these 43 associations were unique to Finland or enriched >20-fold in FinMetSeq 133 
compared to non-Finnish Europeans (NFE). These enriched alleles cluster geographically 134 
like Finnish Disease Heritage mutations, indicating that the distribution of trait-associated 135 
rare alleles may vary significantly between locations within a country.  136 
 137 
We demonstrate that exome sequencing in a historically isolated population that expanded 138 
after recent population bottlenecks is an extraordinarily efficient strategy to discover alleles 139 
with a substantial effect on quantitative traits. As most of the novel, putatively deleterious 140 
trait-associated variants that we identified are unique to or highly enriched in Finland, we 141 
estimate that similarly powered studies of these variants in non-Finnish populations might 142 
require hundreds of thousands or millions of participants.  143 
 144 
RESULTS 145 
Genetic variation  146 
In 19,292 successfully sequenced exomes, we identified 1,318,781 single nucleotide 147 
variants (SNVs) and 92,776 insertion/deletion (indel) variants (Supplementary Tables 1-148 
3, Supplementary Information). Compared to NFE control exomes (gnomAD v2.1, 149 
Extended Data Fig. 1A), FinMetSeq exomes showed depletion of singletons and 150 
doubletons and excess variants with minor allele count (MAC)≥5, particularly for 151 
predicted-deleterious alleles (Extended Data Fig. 1B). 152 
 153 
Association analyses 154 
We tested for association between genetic variants in FinMetSeq and 64 clinically relevant 155 
quantitative traits after standard adjustments for medications and covariates and 156 
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transformation to normality for analyses (Methods, Supplementary Tables 4 & 5). Sixty-157 
two of 64 traits exhibited significant heritability with common SNVs (P<0.05; 158 
5%<h2<53%; Extended Data Fig. 2A, Supplementary Table 6), with substantial 159 
phenotypic and genetic correlations between traits (Extended Data Fig. 2B). 160 
 161 
Single-variant association tests with genetic variants with MAC≥3 among the 3,558 to 162 
19,291 individuals measured for each trait (Supplementary Tables 4 & 5) identified 1,249 163 
associations (P<5×10-7) at 531 variants (Supplementary Table 7); 53 traits associated 164 
with ≥1 variant (Fig. 1A). All 1,249 associations remained significant after multiple testing 165 
adjustment (exome-wide and across the 64 traits using a hierarchical procedure setting 166 
average FDR at 5%, Methods). Using this procedure on the 531 associated variants, we 167 
detected 287 more associations (Supplementary Table 8), most reflecting high correlation 168 
between lipid traits. Of the 531 variants, those at >10x frequency in FinMetSeq compared 169 
to NFE were more likely to be trait-associated (OR=4.92, P=2.6×10-5; Extended Data Fig. 170 
1C).  171 
 172 
After clumping associated variants within 1Mbp and with r2>0.5 into single loci (Methods), 173 
the 531 associated variants represented 262 distinct loci (597 trait-locus pairs, 174 
Supplementary Table 7). The number of associated loci per trait correlated positively 175 
with trait heritability (r=0.38, P=8.8×10-4), with height a notable outlier (Fig. 1B). 176 
 177 
Most variants and loci (61%) associated to a single trait; 4% associated to ≥10 traits. 178 
Overlapping associations (Extended Data Fig. 3A) reflect both phenotypic and genetic 179 
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correlations and the estimated genetic correlation of trait pairs predicts shared loci between 180 
traits (Extended Data Fig. 3B). Gene-based association tests revealed 54 associations with 181 
P<3.88×10-6 and multi-trait FDR<0.05 (Methods, Supplementary Table 9), including ten 182 
traits associated with APOB (Extended Data Fig. 4) and a novel association of SECTM1 183 
with HDL2-C (Extended Data Fig. 5). 184 
 185 
To determine which of the 1,249 single-variant associations are distinct from previous 186 
GWAS findings, we repeated association analysis for each trait conditioning on published 187 
associated variants in the EBI GWAS Catalog (December 2016, Methods); 478 188 
associations at 126 loci remained significant (P<5×10-7), including at least one association 189 
for 48 traits (Supplementary Table 10). Conditionally-associated variants were more 190 
often rare (24% vs. 11%), more likely protein-altering (31% vs. 22%), and more frequently 191 
>10x enriched in FinMetSeq relative to NFE (19% vs. 10%) than associated variants 192 
overall.  193 
 194 
Replication and follow-up 195 
We attempted to replicate the 478 single-variant associations (unconditional and 196 
conditional P≤5×10-7) and follow up 2,120 sub-threshold associations from FinMetSeq 197 
(unconditional 5×10-7<P≤5×10-5 and conditional P≤5×10-5) in 24,776 participants from 198 
three Finnish cohort studies: FINRISK16,17 participants not in FinMetSeq (n=18,215), 199 
Northern Finland Birth Cohort 196618 (n=5,139), and Helsinki Birth Cohort19 (n=1,412), 200 
all imputed using the Finnish SISu v2 reference panel (www.sisuproject.fi). Following 201 
association analysis within each cohort, we conducted meta-analysis of the three 202 
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imputation-based studies to test for replication of FinMetSeq variants (“replication 203 
analysis”), and four-study meta-analysis with FinMetSeq to follow up suggestive 204 
associations (“combined analysis”).  205 
 206 
Of 448 significant variant-trait associations with replication data, 392 (87.5%) replicated 207 
at P<0.05 (Supplementary Table 11). Of the 1,417 sub-threshold associations, 431 208 
reached P<5×10-7 in the combined analysis (Supplementary Table 12); >60% of variants 209 
we could not follow up were absent in the reference panel. 210 
 211 
Among the significant associations from FinMetSeq or combined analysis, 43 were with 212 
26 predicted deleterious variants (six PTVs, 20 missense) that conditional analysis and 213 
literature review suggest are novel (Table 1). Nineteen associations (15 variants) were 214 
significant in FinMetSeq (Table 1; Supplementary Table 11); another 24 associations (16 215 
variants) reached significance in combined analysis (Table 1; Supplementary Table 12). 216 
Of these 43 associations, 34 were with 19 variants either seen only in Finland or enriched 217 
>20-fold in FinMetSeq compared to NFE. Identifying associations for these 19 variants 218 
would have required much larger samples in NFE populations than in FinMetSeq (Fig. 2A, 219 
B). We provide brief summaries relating some of these associations to known biology and 220 
prior genetic evidence (Table 1, expanded version in Supplementary Table 13, 221 
Supplementary Information), highlighting here the most striking findings.  222 
 223 
Anthropometric traits. A predicted damaging missense variant (p.Arg94Cys) in THBS4 224 
45X more frequent in FinMetSeq than in NFE was associated in the combined analysis 225 
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with a mean 5.9 kg decrease in body weight. THBS4 encodes thrombospondin 4, a 226 
matricellular protein found in blood vessel walls and highly expressed in heart and adipose 227 
20. THBS4 may regulate vascular inflammation21 and has been implicated in heart disease 228 
risk22.  229 
 230 
A predicted damaging missense variant (p.Val104Met) in DLK1 177X more frequent in 231 
FinMetSeq than in NFE is associated in the combined analysis with a mean 1.3cm decrease 232 
in height. DLK1 encodes Delta-Like Notch Ligand 1, an epidermal growth factor that 233 
interacts with fibronectin and inhibits adipocyte differentiation. Uniparental disomy of 234 
DLK1 causes Temple and Kagami-Ogata Syndromes, characterized by growth restriction, 235 
hypotonia, joint laxity, motor delay, and early onset of puberty23. Paternally-inherited 236 
common variants near DLK1 are associated with childhood obesity, type 1 diabetes, age at 237 
menarche, and precocious puberty24-26. Homozygous null mutations in the mouse ortholog 238 
Dlk-1 lead to embryos with reduced size, skeletal length, and lean mass27; in Darwin’s 239 
finches, SNVs at this locus have a strong effect on beak size28.  240 
 241 
HDL-C. A predicted deleterious missense variant p.Arg112Trp in CD300LG is associated 242 
in FinMetSeq with a mean 0.95 mmol/l increase in HDL-C and is associated with increased 243 
HDL2-C and ApoA1. This variant, absent in NFE, has an opposite direction of effect from 244 
a previously reported deleterious missense variant in this gene29, which encodes a type I 245 




Amino acids. A stop gain variant (p.Arg722X) in ALDH1L1 is associated in FinMetSeq 248 
with reduced serum glycine levels and is absent in NFE; this trait may increase risk for 249 
cardiometabolic disorders30,31. ALDH1L1 encodes 10-formyltetrahydrofolate 250 
dehydrogenase, which competes with serine hydroxymethyltransferase to alter the ratio of 251 
serine to glycine in the cytosol. Gene-based tests suggest additional PTVs and missense 252 
variants in ALDH1L1 alter glycine levels (P=1.4×10-20, Extended Data Fig. 6, 253 
Supplementary Table 9). 254 
 255 
Ketone bodies. A predicted damaging missense variant (p.Phe517Ser) in ACSS1 is 256 
associated in the combined analysis with increased serum acetate levels and is absent in 257 
NFE. ACSS1 encodes an acyl-coenzyme A synthetase and plays a role in conversion of 258 
acetate to acetyl-CoA. In rodents, increased acetate levels lead to obesity, insulin 259 
resistance, and metabolic syndrome32. 260 
 261 
Trait-associations and disease endpoints 262 
Genotype data from FinnGen33 enabled us to test whether deleterious variants responsible 263 
for our novel trait associations contribute to related disease endpoints. We examined 22 264 
diseases for the 25 available variants in Table 1; three variants were associated with 265 
diseases in FinnGen at Bonferroni threshold P<0.05/(22×25)=9.0×10-5 (Supplementary 266 
Table 14). 267 
 268 
A predicted damaging missense variant (p.Ser328Pro) in KRT40, associated in FinMetSeq 269 
with elevated HDL-C, but absent in NFE, is associated in FinnGen with increased 270 
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pancreatitis risk. While this is the first disease association reported for KRT40, type I 271 
keratins regulate exocrine pancreas homoeostasis34. A 29bp deletion causing a frameshift 272 
in FAM151A is associated in FinMetSeq with decreased total cholesterol in IDL and 273 
decreased IDL particle concentration, is 6.7X more frequent in FinMetSeq than NFE, and 274 
is associated in FinnGen with decreased risk of myocardial infarction. Interpretation of this 275 
association is complicated as the variant is also situated in an overlapping gene (ACOT11) 276 
involved in fatty acid metabolism and lies <1Mbp from a cardioprotective variant in 277 
PCSK9. Finally, a predicted damaging missense variant (p.Arg65Trp) in DBH associated 278 
with a mean 1.0 mmHg decrease in diastolic blood pressure in the combined analysis, is 279 
23.8X more frequent in FinMetSeq than in NFE, and is associated in FinnGen with 280 
decreased risk for hypertension. Distinct loci in this gene and gene-based tests are 281 
associated with mean arterial pressure35,36. 282 
 283 
Replication outside Finland 284 
To assess the generalizability of these novel associations, we attempted to replicate 285 
associations from our combined analysis in the UK Biobank (UKB). Across eight 286 
anthropometric and blood pressure traits for which UKB data are publicly available, our 287 
combined analysis identified 31 trait-variant associations, of which 23 were present in 288 
UKB. Twenty of 23 associations were to variants with MAF>1% in FinMetSeq and 289 
comparable frequency in UKB; 15 (75%) showed association in UKB at 290 
P<0.05/23=2.2×10-3. The three rare variants in this analysis were all >10x more frequent 291 
in FinMetSeq than UKB; none were associated in UKB (Supplementary Table 15). 292 
However, even after adjusting for winner’s curse37, we had <50% power to detect these 293 
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associations in UKB, consistent with the argument that extremely large samples will be 294 
needed in other populations to achieve the power for rare-variant association studies that 295 
we observed in Finland.  296 
 297 
Enriched variants cluster geographically 298 
Given the concentration of Finnish Disease Heritage mutations within regions of late-299 
settlement Finland38, we hypothesized that trait-associated variants discovered through 300 
FinMetSeq might also cluster geographically. Principal component analysis supported this 301 
hypothesis, revealing broad-scale population structure within late-settlement regions 302 
among 14,874 unrelated FinMetSeq participants with known parental birthplaces 303 
(Extended Data Fig. 7). Carriers of PTVs and missense alleles showed more clustering of 304 
parental birthplaces than carriers of synonymous alleles, even after adjusting for MAC 305 
(Supplementary Tables 16A, B). 306 
 307 
To analyze the distribution of variants within late-settlement Finland, we delineated 308 
geographically distinct population clusters using haplotype sharing among 2,644 unrelated 309 
individuals with both parents born in the same municipality (Methods, Extended Data Fig. 310 
8). We compared variant counts across functional classes and frequencies between an 311 
early-settlement reference cluster and 12 clusters containing ≥100 individuals (Extended 312 
Data Fig. 9, Supplementary Tables 17, 18). Clusters representing the most heavily 313 
bottlenecked late-settlement regions (Lapland and Northern Ostrobothnia) displayed a 314 
deficit of singletons and enrichment of intermediate frequency variants compared to other 315 




Variants >10x enriched in FinMetSeq compared to NFE displayed particularly strong 318 
geographical clustering (Supplementary Table 19). We further characterized clustering 319 
for FinMetSeq-enriched trait-associated variants, by comparing mean distances between 320 
birthplaces of parents of minor allele carriers to those of non-carriers (Supplementary 321 
Table 20). Most such variants were highly localized. For example, for rs780671030 in 322 
ALDH1L1, the mean distance between parental birthplaces is 135km for carriers and 323 
250km for non-carriers (P<1.0×10-7, Fig. 3A).  324 
 325 
Finally, we identified comparable geographic clustering between carriers of 35 Finnish 326 
Disease Heritage mutations and carriers of FinMetSeq-enriched trait-associated variants 327 
(Fig. 3B, Methods). Clustering was dramatically greater than that observed for non-carriers 328 
of both sets of variants, suggesting that rare trait-associated variants may be much more 329 
unevenly distributed geographically than previously appreciated.   330 
 331 
DISCUSSION 332 
We demonstrate that a well-powered exome sequencing study of deeply phenotyped 333 
individuals can identify numerous rare variants associated with medically relevant 334 
quantitative traits. The variants we identified provide a useful starting point for studies 335 
aimed at uncovering biological mechanisms and fostering clinical translation. The power 336 
of this study to discover rare-variant associations derives from the numerous deleterious 337 
variants that are enriched in or unique to Finland. Prioritizing the sequencing of multiple 338 
population isolates that have expanded from recent bottlenecks is a strategy for scaling up 339 
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the discovery of rare-variant associations7,39-41. Because genetic drift results in a different 340 
set of alleles to pass through population-specific bottlenecks, enriching some variants and 341 
depleting others, the numerous rare-variant associations that could be identified by 342 
sequencing well-phenotyped samples across multiple isolates could rapidly increase our 343 
understanding of the genetic architecture of complex traits.  344 
 345 
Our results support recent suggestions of continuity between the genetic architectures of 346 
complex traits and disorders classically considered monogenic42,43, by identifying 347 
numerous deleterious variants with large effects on quantitative traits that demonstrate 348 
geographical clustering comparable to that of the mutations responsible for the Finnish 349 
Disease Heritage.  350 
 351 
Using a Finland-specific reference panel44 to impute FinMetSeq variants into array-352 
genotyped samples from three other Finnish cohorts enabled us to identify additional novel 353 
associations. However, the clustering in FinMetSeq of deleterious trait-associated variants 354 
within limited geographical regions and our inability to follow-up >700 sub-threshold 355 
associations from FinMetSeq for which the associated variants were absent in the Finnish 356 
imputation reference panel, emphasize the importance of representing regional 357 
subpopulations in such reference panels, to account for fine-scale population structure.  358 
 359 
The value of rare-variant studies in population isolates will depend on the richness of 360 
phenotypes in sequenced cohorts from these populations. For example, we associated <100 361 
of the >24,000 deleterious, highly enriched variants identified in FinMetSeq with one of 362 
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the 64 quantitative traits studied here. The associations we identified to disease endpoints 363 
in FinnGen hint at the discoveries that will be possible when that database reaches its full 364 
size of 500,000 participants. The insights gained from such efforts will accelerate the 365 
implementation of precision health, informing projects in more heterogeneous populations 366 
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Figure 1. Characterization of associations. 551 
A) Number of genomic loci associated with each trait. Bars are subdivided into common 552 
(MAF>1%, dark blue) and rare (MAF≤1%, light blue). 553 
 554 
B) Relationship between estimated heritability and number of loci detected per trait. Each 555 
trait is colored by trait group. Vertical bars indicate ±2 standard errors. The gray line shows 556 
the linear regression fit to indicate the general trend. The number of independent 557 
individuals used in each point is listed in Supplementary Table 5. Height is the notable 558 
outlier. 559 
 560 
Figure 2. Allelic enrichment in the Finnish population and its effect on genetic 561 
discovery. 562 
A) Relationship between MAF and estimated effect size for associations discovered in 563 
FinMetSeq. Each variant reaching significance in FinMetSeq is plotted, with associations 564 
in Table 1 represented by dark blue points (FinMetSeq MAF) and green points (NFE 565 
MAF). Purple lines indicate 80% power curves for sample sizes of 10,000 and 20,000 at 566 
α=5x10-7.  567 
 568 
B) Same plot as in A, highlighting the variants in Table 1 only reaching significance in the 569 
combined analysis.  570 
 571 
Figure 3. Geographical clustering of associated variants. 572 
A) Example of geographical clustering for a novel trait-associated variant (Table 1). The 573 
map shows birth locations of all 113 parents of carriers (orange) and 113 randomly selected 574 
parents of non-carriers (blue) of the minor allele for rs780671030 in ALDH1L1. 575 
 576 
B) FDH mutations (N=38) geographically cluster (by parental birthplace) similarly to trait-577 
associated variants (Table 1) that are >10x more frequent in FMS than in NFE (N=12) and 578 
more than enriched variants from our combined analysis (N=7). For all variants, carriers 579 
clustered more than non-carriers (center line, median; box limits, upper and lower quartiles; 580 
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Figure Legends (Extended Data Figures) 
Extended Data Fig. 1. Allele frequency comparisons between FinMetSeq and NFE 582 
from gnomAD. 583 
A) Distribution of allelic frequencies between FinMetSeq and gnomAD NFE. The 584 
comparison of allele frequencies shows the excess of variants at higher frequency in 585 
Finland as a result of the multiple bottlenecks experienced in Finnish population history.  586 
 
B) Proportional site frequency spectra between FinMetSeq and gnomAD NFE by variant 587 
annotation class. In general, we find a depletion of the variants in the rarest frequency class, 588 
as well as enrichment of variants in the intermediate to common frequency range. The site 589 
frequency spectra were down-sampled to 18,000 chromosomes for each dataset. 590 
 
C) Comparison of MAFs for trait-associated variants in FinMetSeq and NFE gnomAD. 591 
Plotted in gray background is a 2-D histogram of variants with non-zero allele frequencies 592 
in both gnomAD and FinMetSeq but no trait associations. Variants associated with at least 593 
one trait are colored and scaled inversely proportional to the logarithm of the association 594 
p-value. Variants >10x enriched in FinMetSeq compared to NFE are pink, those <10x 595 
enriched are in blue. The dashed line is the line of equal frequency. Two-sided uncorrected 596 
P-values are from a regression of trait on the count of alternative allele at each variant. The 597 
number of independent individuals used in each point is listed in Supplementary Table 5. 598 
 599 
Extended Data Figure 2. Heritability of and correlations between traits. Traits are in 600 
the same order, clockwise in A, and left to right and top to bottom in B, following the trait 601 
group color key. 602 
A) Heritability estimated in 13,342 unrelated individuals (for abbreviations see 603 
Supplementary Table 4), for details see Supplementary Table 6.  604 
 
B) Heatmap of: 1) absolute Pearson correlations of standardized trait values in upper 
triangle; 2) absolute values of estimated pairwise genetic correlations in lower triangle. 
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Genetic correlations are estimated in 13,342 unrelated individuals. Values below the 
diagonal in gray had trait heritability less than 1.5 times the SE of heritability.  
 
Extended Data Fig. 3. Properties of associations shared between traits. 605 
A) Shared genomic associations by pairs of traits. For traits x and y, color in row x and 606 
column y reflects the number of loci associated with both traits divided by the number of 607 
loci associated with trait x. Traits are presented in the same order as in Extended Data 608 
Figure 2A, and the side and top color bars reflect trait groups.  609 
 610 
B) Relationship between estimated genetic correlation and extent of sharing of genetic 611 
associations. For each trait-pair, the extent of locus sharing is defined as the number of loci 612 
associated with both traits divided by the total number of loci associated with either trait. 613 
Analysis using the absolute value of the Pearson correlation of the residual series results in 614 
a very similar pattern. The number of trait pairs in each x-axis category are as follows: 0-615 
1%: 819; 1-10%: 204, 11-20%: 102; 21-30%: 41; 31-40%: 29; 41-50%: 16, >50%: 13. The 616 
bar within each box is the median, the box represents the upper and lower quartiles, 617 
whiskers extend to 1.5x the interquartile range, and points represent outliers. 618 
 
Extended Data Fig. 4. Gene-based association of extremely rare variants in APOB 619 
with serum total cholesterol. The upper panel shows the distribution of the covariate 620 
adjusted and inverse-normal transformed phenotype. The lower panel displays the 621 
association statistics for each variant included in the gene-based test along with the trait 622 
value for minor allele carriers of each variant (orange triangles). SV.P is the P-value from 623 
the analysis of each variant in a single-variant analysis. The number of independent 624 
individuals in the analysis is 19,291. 625 
 
Extended Data Fig. 5. Gene-based association of rare variants in SECTM1 with HDL2 626 
cholesterol. The upper panel shows the distribution of the covariate adjusted and inverse-627 
normal transformed phenotype. The lower panel displays the association statistics for each 628 
variant included in the gene-based test, along with the trait value for minor allele carriers 629 
of each variant (orange triangles). SV.P is the P-value from the analysis of each variant in 630 
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a single-variant analysis. The number of independent individuals in the analysis is 10,984. 631 
 
Extended Data Fig. 6. Gene-based association of extremely rare variants in ALDH1L1 632 
with glycine levels. The upper panel shows the distribution of the covariate adjusted and 633 
inverse-normal transformed phenotype. The lower panel displays the association statistics 634 
for each variant included in the gene-based test, along with the trait value for minor allele 635 
carriers of each variant (orange triangles). SV.P is the P-value from the analysis of each 636 
variant in a single-variant analysis. The number of independent individuals in the analysis 637 
is 8,206. 638 
 
Extended Data Fig. 7. Population structure of the FinMetSeq dataset, by region. 639 
Population structure, by region, from principal components analysis of exome sequencing 640 
variant data (MAF > 1%), for 14,874 unrelated individuals known parental birthplaces. 641 
Color indicates individuals with both parents born in the same region; gray indicates 642 
individuals with different parental birth regions, or missing information for one parent. 643 
Abbreviations for the regions: Usm, Uusimaa; Swf, Southwest Finland; Stk, Satakunta; 644 
Khm, Kanta-Hame; Prk, Pirkanmaa; Phm, Paijat-Hame; Kyl, Kymenlaakso; SKa, Southern 645 
Karelia; Nka, Northern Karelia; SSv, Southern Savonia; NSv, Northern Savonia; Ctf, 646 
Central Finland; SOs, Southern Ostrobothnia; Osb, Ostrobothnia; COs, Central 647 
Ostrobothnia; NOs, Northern Ostrobothnia; Kai, Kainuu; Lap, Lapland; X, split parental 648 
birthplaces. Large solid circles represent the center of each region.  649 
 
Extended Data Fig. 8. Hierarchical clustering tree produced by fineSTRUCTURE. 650 
We identified 16 subpopulations within the FinMetSeq dataset by applying a haplotype-651 
based clustering algorithm, fineSTRUCTURE, on 2,644 unrelated individuals born by 652 
1955 whose parents were both born in the same municipality (Methods). Each 653 
subpopulation is named based on the most common parental birth location among its 654 
members, with the following abbreviations: NKa, North Karelia; NSv, North Savonia; 655 
SOs, South Ostrobothnia; NOs, North Ostrobothnia; Kai, Kainuu; Lap, Lapland; SuK, 656 
Surrendered Karelia. A map of Finland with regions labeled is supplied for reference. If 657 
multiple subpopulations share the same location label, the subpopulation is further 658 
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distinguished with a numeral. NSv3 is used as an internal reference in enrichment analysis. 659 
See Supplementary Table 17 for more detailed demographic descriptions of each 660 
subpopulation.  661 
 
Extended Data Fig. 9. Regional variation in allele frequencies by functional 662 
annotation. Enrichment of variants by allelic class in regional sub-populations of late 663 
settlement Finland (defined in Supplementary Table 17). Each bin represents the ratio of 664 
variants in the subpopulation compared to the reference subpopulation (NSv3), after down-665 
sampling the frequency spectra of all populations to 200 chromosomes. Pink cells represent 666 
an enrichment (ratio >1), blue cells represent a depletion (ratio <1). Sample sizes and 667 
confidence intervals on each enrichment ratios, and their P-values, are presented in 668 
Supplementary Table 18. The results are consistent with multiple bottlenecks in late 669 
settlement Finland, particularly for populations in Lapland and Northern Ostrobothnia. 670 




METSIM and FINRISK studies:  designs, phenotypes, and sequenced participants 672 
METSIM is a single-site study investigating cardiometabolic disorders and related traits 673 
in 10,197 men randomly selected from the population register of Kuopio, Eastern Finland, 674 
aged 45 to 73 years at initial examination from 2005 to 201015,46. We attempted exome 675 
sequencing of all METSIM study participants. 676 
  677 
FINRISK is a series of health examination surveys based on random population samples 678 
from five (six in 2002) geographical regions of Finland, carried out every five years 679 
beginning in 197247. For exome sequencing, we chose 10,192 participants in the 1992-680 
2007 FINRISK surveys from northeastern Finland (former provinces of North Karelia, 681 
Oulu, and Lapland).  682 
 683 
All participants in both studies provided informed consent, and study protocols were 684 
approved by the Ethics Committees at participating institutions (National Public Health 685 
Institute of Finland; Hospital District of Helsinki and Uusimaa; Hospital District of 686 
Northern Savo). All relevant ethics committees approved this study. 687 
 688 
Selection of traits, harmonization, exclusions, covariate adjustment, and 689 
transformation 690 
Of the 257 quantitative traits measured in both METSIM and FINRISK, we selected 64 for 691 
association analysis in FinMetSeq based on clinical relevance for cardiovascular and 692 
metabolic health (Supplementary Tables 4, 5). We excluded individuals with type 1 693 
diabetes and women who were pregnant at the time of phenotyping from all analyses; 694 
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individuals with T2D from analyses of glycemic traits; and individuals not fasting for at 695 
least 8 hours after their last meal for traits influenced by food consumption. A complete 696 
list of exclusions is in Supplementary Table 5. We adjusted measured values of systolic 697 
and diastolic blood pressures for individuals on antihypertensive medication at the time of 698 
testing48,49, and serum lipid measures for individuals on lipid regulating medications50,51. 699 
Trait adjustments are listed in Supplementary Table 5. 700 
 701 
We prepared quantitative traits for association analysis separately for METSIM and 702 
FINRISK by linear regression on trait-specific covariates after log transforming skewed 703 
variables. Covariates for regression analyses included: age and age2 (METSIM); sex, age, 704 
age2, and cohort year (FINRISK). Trait transformations and trait-specific covariates are 705 
listed in Supplementary Table 5. Several traits were adjusted for sex hormone treatment, 706 
which included women on contraceptives or hormone replacement therapy. We 707 
transformed residuals from these initial regression analyses to normality using inverse 708 
normal scores.  709 
 710 
Exome sequencing 711 
We carried out exome sequencing in two phases.  712 
 713 
Phase 1 We quantified 10,379 DNA samples with PicoGreen (ThermoFisher Scientific) 714 
and randomly parsed samples with adequate DNA (>250ng) into cohort-specific files. We 715 
then re-arrayed samples to ensure equal numbers of METSIM and FINRISK samples on 716 
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each 96-well plate, alternating samples between studies in consecutive positions within and 717 
across plates, to minimize between-study batch effects. 718 
 719 
Using 100-250ng input DNA, we constructed dual indexed libraries using the HTP Library 720 
Kit (KAPA Biosystems, target insert size of 250bp), pooling twelve libraries prior to 721 
hybridization to the SeqCap EZ HGSC VCRome (Roche) exome reagent. After estimating 722 
the concentration of each captured library pool by qPCR (Kapa Biosystems) to produce 723 
appropriate cluster counts for the HiSeq2000 platform (Illumina), we generated 2x100bp 724 
paired-end sequence data yielding ~6 Gb per sample to achieve a coverage depth of ≥20x 725 
for ≥70% of targeted bases for every sample. 726 
 727 
Phase 2 We quantified, prepared, pooled, and captured 9,937 samples just as in Phase 1. 728 
Here we generated 2×125bp paired-end sequencing reads on the HiSeq2500 1T to achieve 729 
the same coverage as in Phase 1. 730 
 731 
Contamination detection, sequence alignment, sample QC, and variant calling  732 
We aligned sequence reads to human genome reference build 37 (bwa-mem, v0.7.7), 733 
realigned indels (GATK52 IndelRealigner v2.4), and marked duplicates (picard 734 
MarkDuplicates, v1.113; http://broadinstitute.github.io/picard) and overlapping bases 735 




For each sample, we required SNV genotype array concordance >90% if SNV array data 738 
were available, excluding samples with estimated contamination >3% or sample swaps 739 
compared to existing genotype data (verifyBamID53, v1.1.1; Supplementary Table 1).  740 
 741 
We called SNVs and short indels with GATK52 (v3.3, using recommended best practices) 742 
for all targeted exome bases and 500bp of sequence up and downstream of each target 743 
region using HaplotypeCaller. We merged calls in batches of 200 individuals using 744 
CombineGVCFs and recalled genotypes for all individuals at all variable sites with 745 
GenotypeGVCFs. 746 
 747 
After merging genotypes for the 19,378 samples that passed preliminary QC checks, we 748 
filtered SNVs and indels separately using the recommended best practices for Variant 749 
Quality Score Recalibration (VQSR). We used the true positive variants in the GATK 750 
resource bundle (v2.5; build37) to train the VQSR model after restricting to sites in targeted 751 
exome regions. After assessment with VQSR, we retained variants for which we identified 752 
≥99% of true positive sites used in the training model for both SNVs and indels.  753 
 754 
Following initial variant filtering, we decomposed multi-allelic variants into bi-allelic 755 
variants, left-aligned indels, and dropped redundant variants using vt54 (version 0.5). We 756 
filtered variants with >2% missing calls and/or Hardy-Weinberg p-value<10-6. We 757 
additionally removed variants with an overall allele balance (alternate AC/sum of total AC) 758 
<30% in genotyped samples. We excluded 86 individuals with >2% missing variant calls 759 




Array genotypes, genotype imputation, and integrated exome+imputation panel 762 
For all but 1,488 participants (57 METSIM, 1,431 FINRISK), previously generated array 763 
genotypes were available17,55, with which we generated three datasets: (1) a merged array-764 
based call set of all variants present in 90% of array-genotyped individuals across both 765 
cohorts; (2) a merged array-based Haplotype Reference Consortium (HRC) v1.1 imputed 766 
dataset using the Michigan Imputation Server56,57; (3) an integrated data set containing 767 
HRC imputed genotypes and exome-sequence variants (excluding all individuals without 768 
array data, and using the sequence-based genotypes where there was overlap between 769 
sequenced and imputed genotypes).  770 
 771 
Annotation 772 
We annotated the final set of sequence variants passing QC using Ensembl’s variant effect 773 
predictor (VEP v76)58 employing five in silico algorithms to predict the functional impact 774 
of missense variants: PolyPhen2 HumDiv and HumVar59, LRT60, MutationTaster61, and 775 
SIFT62. 776 
 777 
Association testing 778 
Single variants 779 
We carried out single-variant association tests for transformed trait residuals with genotype 780 
dosages for variants with MAC≥3 assuming an additive genetic model, using the 781 
EMMAX63 linear mixed model approach, as implemented in EPACTS (v3.3.0; 782 
http://genome.sph.umich.edu/wiki/EPACTS), to account for relatedness between 783 
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individuals. We used genotypes for sequenced variants with MAF≥1% to construct the 784 
genetic relationship matrix (GRM).  785 
 786 
Conditioning on associated variants from prior GWAS 787 
To differentiate association signals identified here from known associations, for each trait 788 
we performed exome-wide association analysis conditioning on variants previously 789 
associated (P<10-7) with that trait in the EBI GWAS catalog 790 
(https://www.ebi.ac.uk/gwas/downloads; December 4, 2016 version)64, publications, or 791 
manuscripts in preparation55,65-67. The keywords from the GWAS catalog we used to assign 792 
known variants to each trait are in Supplementary Table 21. We also manually curated 793 
published associations for specific metabolites65,68. 794 
 795 
Using the combined HRC+exome panel, we pruned each trait-specific list of associated 796 
variants (“GWAS variants”) based on linkage disequilibrium (LD) (r2>0.95). Of 23 GWAS 797 
variants absent in the HRC+exome panel, we identified a proxy (r2>0.80) variant for 17; 798 
we excluded the remaining six variants from conditional analysis. The variants included in 799 
conditional analysis are listed in Supplementary Table 22. We extracted genotypes for 800 
variants used in conditional analysis from the HRC+exome panel and converted dosages 801 
to alternate allele counts by rounding to the nearest integer (0, 1, or 2). For conditional 802 
analyses, we imputed missing genotypes for the individuals without array data using the 803 
mean genotype. We then ran association analysis using the same linear mixed model 804 
approach as in unconditional analysis but including the complete set of pruned GWAS 805 
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variants as covariates in the association test. We then evaluated the novelty of conditional 806 
associations by searching OMIM, ClinVar, and the literature. 807 
 808 
Defining loci 809 
To identify the number of distinct associations for each trait, we performed LD clumping 810 
using Swiss (https://github.com/welchr/swiss) of variants with (1) unconditional P<5×10-7 811 
or (2) both unconditional and conditional P<5×10-5 for at least one trait. For each variant 812 
in this subset, we provided Swiss with the minimum unconditional p-value across all traits. 813 
The clumping procedure starts with the variant with the smallest p-value, merges into one 814 
locus all variants within ±1Mbp that have r2>0.5 with the index variant, and iterates this 815 
process until no variants remain.  816 
 817 
Calculating effects and variance explained of individual variants 818 
For novel variants highlighted in Table 1 we evaluated the effect of each variant on the 819 
trait values by calculating the mean trait value in carriers and non-carriers. As the effect 820 
estimates from our association tests are standardized, we calculated variance explained for 821 
a given variant with the equation 2f (1-f)?̂?2, where f is the minor allele frequency and ?̂? is 822 
the estimated effect size. The variance explained is in Supplementary Table 10. 823 
 824 
Gene-based testing 825 
We carried out gene-based association tests using the mixed model implementation of 826 
SKAT-O69, considering three different, but nested, sets of variants (variant “masks”):  827 
 
 35 
(1) PTVs at any allele frequency with VEP annotations: frameshift_variant, 828 
initiator_codon_variant, splice_acceptor_variant, splice_donor_variant, stop_lost, 829 
stop_gained;  830 
(2) PTVs included in (1) plus missense variants with MAF<0.1% scored as “damaging” or 831 
“deleterious” by all five functional prediction algorithms; 832 
(3) PTVs included in (1) plus missense variants with MAF<0.5% scored as “damaging” or 833 
“deleterious” by all five algorithms. 834 
 835 
For each trait and mask, we only tested genes with at least two qualifying variants. Each 836 
mask contained a different number of genes with at least two qualifying variants: up to 837 
7,996, 12,795, and 12,890 for the three masks, respectively. The exact number of genes 838 
tested varied by trait due to sample size. We first used a Bonferroni-corrected exome-wide 839 
threshold for 12,890 genes, which corresponds to a threshold of P<3.88×10-6. Analogous 840 
to single-variant association, we passed genes meeting this association threshold forward 841 
for additional consideration with hierarchical FDR correction, described below. 842 
 843 
Hierarchical FDR correction for testing multiple traits and variants 844 
To control for multiple testing across 64 traits, we adopted an FDR controlling procedure70, 845 
using a two-stage hierarchical strategy (described in Supplementary Information). Stage 846 
1 identifies the set of R variants (or genes) associated with at least one trait (P<5×10-7 for 847 
single-variant unconditional results and P<3.88×10-6 for gene-based results), controlling 848 
genome-wide FDR across all variants at 0.05. Stage 2 identifies all traits associated with 849 




Genotype validation  852 
We validated exome sequence-based genotype calls using Sanger sequencing for METSIM 853 
carriers of 13 trait-associated very rare variants with MAF<0.1% in seven genes, finding 854 
concordance for 107 of 108 (99.1%) non-reference genotypes evaluated. 855 
 856 
Replication in additional Finnish cohorts 857 
We attempted to replicate significant single-variant associations (P<5×10-7) and follow-up 858 
suggestive single-variant associations (P<5×10-5) using imputed array data from up to 859 
24,776 individuals from three cohort studies: Northern Finland Birth Cohort 1966 860 
(NFBC1966)18, the Helsinki Birth Cohort Study (HBCS)19, and FINRISK study 861 
participants not included in FinMetSeq16,17.  862 
 863 
For each cohort, prior to phasing we performed genotype quality control batch-wise using 864 
standard quality thresholds. We pre-phased array genotypes with Eagle71 (v2.3) and 865 
imputed genotypes genome-wide with IMPUTE72 (v2.3.1) using 2,690 sequenced Finnish 866 
genomes and 5,092 sequenced Finnish exomes. We assessed imputation quality by 867 
confirming sex, comparing sample allele frequencies with reference population estimates, 868 
and examining imputation quality (INFO score) distributions. We excluded any variant 869 
with INFO<0.7 within a given batch from all replication/follow-up analyses.  870 
 871 
For each cohort, we matched, harmonized, covariate adjusted, and transformed available 872 
phenotypes as described above for FinMetSeq, and ran single-variant association using the 873 
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EMMAX linear mixed model implemented in EPACTS, after generating kinship matrices 874 
from LD-pruned (command: plink --indep-pairwise 50 5 0.2) directly genotyped variants 875 
with MAF>5%. 876 
 877 
Association to disease endpoints  878 
From >1,100 disease endpoints available for analysis in FinnGen, we selected 22 we 879 
considered most relevant to the traits analyzed in FinMetSeq, identifying variant 880 
associations as described in Tabassum et al.33.  881 
 882 
Association replication in UK Biobank 883 
For eight FinMetSeq anthropometric and blood pressure traits available in UKB (height, 884 
weight, BMI, hip circumference, waist circumference, fat percentage, systolic blood 885 
pressure, and diastolic blood pressure), we extracted, for variants reaching P<5x10-7 in our 886 
combined analysis, trait-variant association statistics from http://www.nealelab.is/uk-887 
biobank. Seven of the eight traits had at least one associated variant and 23 of the total of 888 
31 variants were available in UKBB. A comparison of association results is in 889 
Supplementary Table 15. 890 
 891 
Population genetic analyses 892 
Identifying unrelated individuals  893 
To identify nearly independent common SNVs, we removed SNVs with MAF<5% and 894 
pruned the remaining SNVs in windows of 50 SNVs, in steps of 5 SNVs, such that no pair 895 
of SNVs had r2>0.2. We used KING73 to estimate pairwise relationships among the exome-896 
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sequenced individuals,  removing one individual from each pair inferred by KING to have 897 
a relationship of 3rd degree or closer, yielding 14,874 unrelated individuals for population 898 
genetic analyses.  899 
 900 
Enrichment of predicted-deleterious alleles in Finland 901 
We assessed enrichment of predicted-deleterious alleles in Finland by comparing the 902 
14,874 nearly unrelated FinMetSeq individuals to the 14,944 NFE control exomes in 903 
gnomAD (after removing NFE individuals from countries with substantial Finnish 904 
populations, Estonia and Sweden). We analyzed the two most common alleles at each site 905 
with base quality score >10, mapping quality score >20, and coverage equal to or greater 906 
than that found in ≥80% of variable sites (17.73X in FinMetSeq, 32.27X in gnomAD), 907 
resulting in ~38.6 Mbp for comparisons. We contrasted the proportional site frequency 908 
spectra for FinMetSeq and NFE for five functional variant categories (PTVs, missense, 909 
synonymous, UTR, and intronic variants) after down-sampling both datasets to 18,000 910 
chromosomes. 911 
 912 
We also assessed the enrichment of deleterious alleles within subpopulations of the 913 
FinMetSeq dataset. We applied Chromopainter and fineSTRUCTURE on 2,644 unrelated 914 
FinMetSeq individuals whose parents were both born in the same municipality to identify 915 
16 sub-population clusters74 (Supplementary Information). Of the 16 clusters, we used 916 
as the reference population a cluster for which the highest proportion of the parents of its 917 
members were from early-settlement Finland (NSv3, Supplementary Table 17). We used 918 
the twelve clusters with >100 members in subsequent analyses (Supplementary Table 919 
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17). We then compared the ratio of the site frequency spectra to the reference for PTVs, 920 
missense, and synonymous variants, down-sampling both datasets to 200 haploid 921 
chromosomes. For each comparison, we computed statistical evidence for enrichment or 922 
depletion at a given allele count bin by exact binomial test against a null of equal number 923 
of variants found in both the test and reference cluster. 924 
 925 
Geographical clustering of predicted functionally deleterious alleles 926 
We first generated a distance matrix tabulating the pairwise geographical distance between 927 
the birthplaces of all available parents of unrelated sequenced individuals. For each variant 928 
of interest, we computed for the minor allele carriers in FinMetSeq the mean distance 929 
among all parent pairs. We evaluated statistical significance of geographical clustering by 930 
comparing the observed mean distance to mean distances for up to 10,000,000 sets of 931 
randomly drawn non-carrier individuals matched by cohort status and number of parents 932 
with birthplace information available. Birthplaces of carrier and non-carrier individuals 933 
were plotted on a map of Finland, including regions that were ceded prior to WW2 (© 934 
Karttakeskus Oy, 2001). 935 
 936 
To assess whether PTVs or missense variants may be more geographically clustered than 937 
synonymous variants, we first identified a set of near-independent variants (r2>0.02) with 938 
MAC≥3 and MAF5% among the 14,874 unrelated individuals. For each variant, we 939 
computed the mean pairwise geographical distance between the birthplaces across all pairs 940 
of the available parents of carriers of the minor allele and regressed this mean distance on 941 
variant class (PTVs, missense, or synonymous) and MAC, MAC2, and MAC3 942 
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(Supplementary Table 16). For those variants in gnomAD, we also assessed whether 943 
variants enriched in FinMetSeq compared to NFE are more likely to be geographically 944 
clustered. As above, we computed the mean pairwise distances among parents of carriers 945 
of the minor allele and regressed mean distance on the logarithm of enrichment and MAC, 946 
MAC2, and MAC3 (Supplementary Table 19). In both analyses we assessed a model with 947 
the interaction terms but report only the model without interactions if the interactions were 948 
not significant. 949 
 950 
Heritability estimates and genetic correlations 951 
We used genome-wide array genotype data on the 13,326 unrelated individuals for whom 952 
both exome sequence and array data were available to estimate heritability and genetic 953 
correlations for the 64 traits. We constructed a GRM with PLINK75 (v.1.90b, 954 
https://www.cog-genomics.org/plink2) by applying additional filters for MAF>1% and 955 
genotype missingness rate <2% to the set of previously-used genotyped SNVs, leaving 956 
205,149 SNVs for GRM calculation. We used the exact mixed model approach of biMM76 957 
(v.1.0.0, http://www.helsinki.fi/~mjxpirin/download.html) to estimate the heritability of 958 
our 64 traits and the genetic correlation of the 2,016 trait pairs. 959 
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